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Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne RNA virus of the genus Alphavirus that is
responsible for a significant disease burden in Central and South America through sporadic outbreaks into human
and equid populations. For humans, 2 to 4% of cases are associated with encephalitis, and there is an overall case
mortality rate of approximately 1%. In mice, replication of the virus within neurons of the central nervous system
(CNS) leads to paralyzing, invariably lethal encephalomyelitis. However, mice infected with certain attenuated
mutants of the virus are able to control the infection within the CNS and recover. To better define what role T cell
responses might be playing in this process, we infected B cell-deficient MT mice with a VEEV mutant that induces
mild, sublethal illness in immune competent mice. Infected MT mice rapidly developed the clinical signs of severe
paralyzing encephalomyelitis but were eventually able to control the infection and recover fully from clinical illness.
Recovery in this system was T cell dependent and associated with a dramatic reduction in viral titers within the
CNS, followed by viral persistence in the brain. Further comparison of the relative roles of T cell subpopulations
within this system revealed that CD4 T cells were better producers of gamma interferon (IFN-) than CD8 T cells
and were more effective at controlling VEEV within the CNS. Overall, these results suggest that T cells, especially
CD4 T cells, can successfully control VEEV infection within the CNS and facilitate recovery from a severe viral
encephalomyelitis.
Venezuelan equine encephalitis virus (VEEV) is a mos-
quito-borne RNA virus of the genus Alphavirus that is respon-
sible for a significant disease burden in Central and South
America through sporadic outbreaks into human and equid
populations (20, 57). The most recent major outbreak occurred
in 1995 with 75,000 to 100,000 human cases spread between
Columbia and Venezuela (59). For humans, only 1 to 2% of
cases progress to full-blown encephalitis, though roughly 50%
of those cases are fatal (58). In equid populations, however, the
mortality rate is much higher and is often over 50% (56).
Because of the high probability of future natural outbreaks, as
well as its potential use as a bioterrorism agent, VEEV remains
a significant public health concern (43). Currently, there are no
therapeutics or licensed vaccines available for human use.
Work with multiple infection models has shown that both
the innate and adaptive arms of the host immune response are
involved in successful control of viruses that target central
nerve system (CNS) neurons (21). Disruption of the type I
interferon system dramatically decreases the average survival
time of mice infected with VEEV, as well as of those infected
with Sindbis and West Nile viruses (45, 46, 60). Studies per-
formed with a variety of neuronotropic viruses, including Sind-
bis and West Nile viruses, have clearly demonstrated that the
development of a virus-specific antibody response is a critical
step in both limiting viral spread and facilitating noncytolytic
clearance of infectious virus from neurons within the brain (14,
32). / T cell responses also help limit lethality in many of
these models by directly killing infected cells, producing anti-
viral cytokines, and/or enhancing the production and quality of
virus-specific antibody (4, 38, 52, 54). In the case of Sindbis
virus, the T cell compartment was able to dramatically restrict
viral replication in the CNS in the absence of antiviral anti-
bodies, partly through a gamma interferon (IFN-)-dependent
mechanism (5). While numerous components of the host im-
mune system play a role in mediating protection or recovery
from neuronotropic virus infection, the specific mechanisms by
which the host is able to eliminate virus from CNS neurons,
while leaving these critical, irreplaceable cells intact, remain
unknown.
Our current understanding of VEEV pathogenesis comes
primarily from work performed using a well-established mouse
model of infection and disease that closely mirrors many as-
pects of disease in humans and horses (18). Following periph-
eral inoculation into the footpad of a mouse, a delivery method
that mimics the natural route of infection by mosquito bite, the
virus initiates a biphasic course of infection in which initial
replication within the skin-draining lymph node as well as
other secondary lymphoid tissue seeds a high-titer serum vire-
mia (35). The viremia facilitates virus invasion of the CNS,
initially through nonmyelinated olfactory neurons within the
nasal neuroepithelium (11, 35). This leads to a second phase of
infection characterized by rapid replication and spread though
CNS neurons and the eventual development of paralyzing en-
cephalitis (10, 19). Infection of inbred mice with most strains of
VEEV results in 100% mortality (56). Due to the extreme
lethality of the virus, efforts to understand the host mecha-
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nisms involved in mediating recovery from VEEV-induced en-
cephalomyelitis have been hampered by the lack of a relevant
model system in which such a recovery could be reliably ob-
served.
Using a fixed cDNA clone (pVR3000) of the Trinidad Don-
key strain of VEEV as a starting point, our laboratory has
generated a panel of genetically defined VEEV mutants that
are attenuated in vivo compared to virus derived from the
parental pVR3000 clone (1, 3, 12, 19, 60). The use of these
mutants, which are attenuated at various definable stages of in
vivo infection, has facilitated the dissection of the sequence of
host-virus interactions that give rise to pathogenesis and/or
immunity during VEEV infection (1, 3, 35). One of these
laboratory-generated mutants, labeled V3533, differs from the
parental V3000 virus at only two residues (E76K and K116E),
both within the E2 glycoprotein, and yet these changes are
sufficient to convert an invariably lethal virus into one that is
nonlethal in immunocompetent C57BL/6 mice (1). Subcutane-
ous infection of C57BL/6 mice with V3533 resulted in neuro-
invasion followed by rapid clearance. This reduction in patho-
genicity did not result from an alteration of CNS cellular
tropism, as both V3000 and V3533 exclusively infected neurons
within the brain (data not shown). Thus, infection with V3533
provided a model system to study successful control of VEEV
infection within the CNS.
In order to identify the components of a successful immune
response to VEEV infection within the CNS, we infected a
number of immunodeficient mouse strains with V3533 and
assessed disease outcome. Infection of Rag1/ mice with
V3533 resulted in nearly total lethality, while infection of B
cell-deficient MT mice resulted in nearly total recovery, dem-
onstrating that recovery from V3533 infection was dependent
upon an adaptive immune response and that while antibody
production contributed to recovery, it was not required. Fur-
ther studies demonstrated that both CD4 and CD8 T cells
had direct antiviral effects within the CNS and that both were
required for maximal control of V3533 infection.
MATERIALS AND METHODS
Viruses. The isolation of wild-type V3000 and the V3533 mutant of VEEV, as
well as the generation of the pVR3000 and pVR3533 molecular clones, has been
described previously (1, 13). Virus stocks of V3533 were generated, using a
T7-specific mMessage mMachine in vitro transcription kit (Ambion), by in vitro
transcription from a linearized plasmid, pVR3533, which encodes the full-length
V3533 cDNA. In vitro-generated transcripts were then electroporated into
BHK-21 cells by the use of a Bio-Rad electroporator as described previously (1).
Culture supernatants were harvested 18 h after electroporation, clarified by
centrifugation at 3,000 rpm for 20 min, and stored as single-use aliquots at
80°C. Viral titers were determined by standard plaque assays on BHK-21 cells,
as previously described (53).
Mouse studies. Rag1/ and MT mice (both on the C57BL/6 background)
were obtained from the Jackson Laboratory (Bar Harbor, ME) and bred in-
house under specific-pathogen-free conditions. C57BL/6 mice were purchased
from the Jackson Laboratory as needed. All experimental manipulation of mice
was performed in a biosafety level 3 animal facility following a 7-day acclimati-
zation period. For infections, 6-to-10-week-old female mice were anesthetized
via intraperitoneal (i.p.) injection with a mixture of ketamine (50 mg/kg of body
weight) and xylazine (15 mg/kg of body weight) and then inoculated in the left
rear footpad with 103 PFU of virus in diluent (phosphate-buffered saline [PBS],
1% donor calf serum, Ca2, Mg2). Mock-infected mice received diluent alone.
Weight loss and disease score were assessed daily for infected animals. The scale
used for disease scoring was as follows: 0, no signs of disease; 1, hunching; 2,
ruffled fur; 3, ataxia, imbalance; 4, conjunctivitis; 5, paralysis of one or both hind
limbs; and 6, moribund. This scale was based on the temporal order of ascending
symptoms in MT mice following V3533 infection. Mice that lost more than 20%
(following V3000 infection) or 35% (following V3533 infection) of their starting
weight or became moribund were euthanized according to University of North
Carolina (UNC) Institutional Animal Care and Use Committee (IACUC) guide-
lines.
Virus titers. To assess VEEV titers in vivo, infected mice were sacrificed, bled,
and then perfused through the heart with 10 ml of PBS. Spleen, draining pop-
liteal lymph node, brain, and spinal cord tissues were then removed, weighed,
and frozen in diluent at 80°C. Tissues were then thawed, homogenized, and
used to infect BHK-21 cells in a standard plaque assay.
In vivo depletions. MT mice received i.p. injections of 0.5 mg of depletion
antibody in 0.1 ml of PBS 24 h prior to V3533 infection, 24 h following infection,
and every 72 h subsequently until the termination of the experiment at day 25
postinfection. The depleting antibodies used were 17A2 (CD3), GK1.5 (CD4),
2.43 (CD8), and LTF2 (isotype control) (all Bio X Cell). At day 25 postinfec-
tion, mice were bled and then sacrificed by exsanguination. Brains and spinal
cords were collected for titering as described above, and spleens were collected
to assess depletion efficacy by flow cytometry.
Quantification of CNS leukocytes and flow cytometry. Mock- and V3533-
infected mice were sacrificed by exsanguination and perfused with PBS. Brains
and spinal cords were harvested, minced, and then incubated for 1.5 h with
vigorous shaking at 37°C in digestion medium (RPMI medium, 1% fetal calf
serum, 25 mM HEPES, 1.25 mg/ml collagenase A [Roche]). Homogenates were
then passed through a 40-m-pore-size strainer and pelleted through 25% Per-
coll (GE Healthcare) in medium (RPMI medium, 1% fetal calf serum, 25 mM
HEPES) for 20 min at 800  g. The resulting pellets were then resuspended in
30% Percoll, overlaid above 70% Percoll, and centrifuged for 20 min at 800  g.
The interface was collected and washed with media, and the absolute number of
live cells in each sample was then determined by trypan blue exclusion. Cells
were washed in flow cytometry wash buffer (1 Hanks’ balanced salt solution,
1% fetal calf serum, 0.1% sodium azide) and then stained with the following
antibodies: anti-CD45-biotin coupled with streptavidin-conjugated PerCP, anti-
anti-CD11b–phycoerithrin–Cy7 (anti-CD11b–PE–Cy7), anti-major histocompat-
ibility complex class II–allophycocyanin (anti-MHC class II-APC), anti-Ly6G-
fluorescein isothiocyanate (anti-Ly6G-FITC) (clone 1A8), and anti-CD3ε-PE
(all eBioscience) and anti-CD4-Pacific Blue and anti-CD8-Pacific Orange (both
Caltag). All staining was done in the presence of anti-mouse FcRII/III (clone
2.4G2; BD Pharmingen) to prevent nonspecific antibody binding. Following
staining, samples were fixed in 2% paraformaldehyde–PBS and analyzed using a
CyAn flow cytometer and Summit 5.2 software (Dako). Absolute numbers of
each specific cell type were calculated by determining the total number of live
cells within a sample by trypan blue exclusion and then multiplying that number
by the percentage of live cells within the sample bearing the appropriate surface
staining profile.
ex vivo analysis of CNS leukocytes. Leukocytes were isolated as described
above. For samples receiving no ex vivo stimulus, cells were cultured in T cell
culture media (RPMI medium, 10% fetal calf serum, 50 M -mercaptoethanol)
with 3 g/ml brefeldin A (eBioscience) for 4 h at 37°C. For samples receiving
stimulus, cells were cultured in T cell culture media with 50 ng/ml phorbol
myristate acetate (PMA) and 500 ng/ml ionomycin for 6 h at 37°C, with brefeldin
A added for the last 4 h. CD107a staining was performed during brefeldin A
treatment, in the presence of 2 M monensin and 1:100 anti-CD107a-AF488 or
an isotype control (eBioscience). Cells were then washed in flow cytometry wash
buffer and stained with the following antibodies: anti-CD69-PE-Cy5 and anti-
CD3ε-PE (both eBioscience) and anti-CD4-Pacific Blue and anti-CD8-Pacific
Orange (both Caltag). Following surface staining, cells were washed twice and
then simultaneously fixed and permeabilized in Cytofix/Cytoperm (BD Bio-
sciences) for 30 min. Permeabilized samples were stained for intracellular ex-
pression using the following antibodies: anti-Ki-67–FITC, anti-IFN-–PE–Cy7,
anti-TNF-–FITC, anti-IL-2–APC, anti-IL-10–APC, anti-IL-17–APC, or the ap-
propriate isotype controls (all eBioscience). All staining was done in the presence
of anti-mouse FcRII/III (2.4G2; BD Pharmingen) to prevent nonspecific anti-
body binding. Samples were then washed twice in Cytoperm/Cytowash (BD
Biosciences) and then analyzed on a CyAn flow cytometer.
RESULTS
V3533 provides a relevant model of viral clearance and
recovery. Following subcutaneous, footpad injection of
C57BL/6 mice with 106 PFU of V3533, the early stages of viral
replication and spread were similar to those observed previ-
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ously with the more virulent parental virus, V3000 (Fig. 1A and
data not shown) (19). Virus in the draining popliteal lymph
node, spleen, and serum was first observed by 24 h postinfec-
tion. The virus first became detectable in the brain by a plaque
assay at day 2 postinfection, while titers in secondary lymphoid
organs and serum were reduced considerably by this time
point. Viral titers peaked within the CNS around day 4, but
unlike wild-type virus that maintained high titers within the
CNS until the inevitable death of the host (data not shown),
titers of V3533 began to decline by day 6, and by day 8,
infectious virus was no longer detectable by plaque assay. Rep-
lication of V3533 within the CNS was associated with a small
but significant loss of weight relative to the results seen with
mock-infected mice in multiple independent experiments (Fig.
1B and 2). Upon clearance, infected mice began regaining
weight and eventually stopped exhibiting outward signs of dis-
ease. Thus, V3533 provides a model of VEEV infection in
which the host is able to successfully clear the virus from the
CNS and recover from clinical illness.
Antibody production is not required for recovery from
V3533-induced encephalomyelitis. The role of the adaptive
component of the immune system in mediating protection or
recovery during VEEV infection has been tested primarily in
the context of vaccinated animals or animals receiving passive
transfer of immune sera. While these studies have been in-
structive, we were interested in what role the adaptive response
could play during the infection of a naïve animal. To answer
this question, we determined whether the observed control of
V3533 by C57BL/6 mice was dependent on the adaptive arm of
the immune system.
Rag1/ mice, which lack functional B and T cells, as well as
FIG. 1. V3533 induces mild, transient disease followed by clear-
ance in C57BL/6 mice. (A) Female C57BL/6 mice (7 to 10 weeks old)
were inoculated with 106 PFU of V3533 by injection in the left rear
footpad. At the indicated days postinfection (Day P.I.), serum, spleen,
brain, and spinal cord samples were collected from V3533-infected
mice and homogenized. The amount of infectious virus present in
serum, spleen, brain, and spinal cord samples was then quantified by
plaque assays of BHK-21 cells. Data are presented as the means 
standard deviations of results pooled from two independent experi-
ments with 3 to 10 animals per time point. Dotted lines represent the
limit of detection. (B) Female C57BL/6 mice (7 to 10 weeks old) were
inoculated with 103 PFU of wild-type VEEV (V3000) or 106 PFU of
V3533 by injection in the left rear footpad. Mock-infected mice were
infected with diluent alone. Mice were weighed daily, with those losing
more than 20% of their starting weight being euthanized as required by
UNC IACUC regulations. *, P 	 0.05 by Mann-Whitney testing.
FIG. 2. Rag1/ mice succumb to V3533 infection, whereas MT
mice recover. Female MT or Rag1/ mice (7 to 10 weeks old) were
inoculated with 103 PFU of V3533 by injection in the left rear footpad.
C57BL/6 mice received 106 PFU of V3533. (A) Mice were weighed
daily, with those losing more than 35% of their starting weight being
euthanized as required by UNC IACUC regulations. (B) Mice were
scored for the development of encephalomyelitis based on the follow-
ing scale: 1, hunched posture; 2, ruffled fur; 3, ataxia, imbalance; 4,
conjunctivitis; 5, hind limb paresis, paralysis; 6, moribundity. Each data
point represents the mean  standard error of the mean (SEM) of the
results obtained with 6 animals per group from a single representative
experiment.
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MT mice, which lack functional B cells, were infected with
103 PFU of V3533 subcutaneously in the footpad. Rag1/
mice initially behaved similarly to wild-type mice, losing little
or no weight and showing no outward signs of disease for the
first 4 days postinfection (Fig. 2). At day 4, infected Rag1/
mice began losing weight and by day 8 postinfection had lost
roughly 20% of their starting weight. They also developed
clinical signs of disease, including hunched posture, ruffled fur,
ataxia, and a marked reduction in cage exploration. Weight
loss and clinical signs of disease in infected Rag1/ mice
progressed rapidly between days 4 and 8 postinfection, but the
clinical condition of the animals then stabilized, and over the
next 10 days both weight and clinical score remained virtually
unchanged. Starting around day 18 postinfection, however,
infected Rag1/ mice suffered further weight loss, culminat-
ing in death. V3533 infection of Rag1/ mice resulted in 93%
lethality (n 
 15) over 40 days of observation, with an average
survival time (AST) of 30  5 days. The differences in disease
outcome observed between C57BL/6 and Rag1/ mice clearly
demonstrated that successful control of V3533 infection is de-
pendent upon an intact adaptive immune response.
The importance of an intact antibody response was demon-
strated by following V3533 infection of MT mice. Between
days 4 and 9 postinfection, MT mice lost about 30% of their
starting weight and developed the outward signs of severe
encephalomyelitis, including convulsions, conjunctivitis, and
hind-limb paresis or paralysis. This dramatically enhanced pa-
thology, compared with the much milder disease observed in
wild-type mice, illustrated the critical role that antibody pro-
duction played in mounting a successful response to VEEV
infection. Surprisingly, despite the extremely severe morbidity
observed, the vast majority (92.7% [64/69]) of these animals
went on to recover. Recovery of MT mice was somewhat
protracted, with mice not regaining their full starting weights
until weeks later. Most outward signs of encephalomyelitis or
febrile illness disappeared in recovered MT mice, though
these animals retained a slight tentativeness in their move-
ments that was still observable 15 weeks after infection. The
stark contrast in disease outcome following V3533 infection in
MT mice versus Rag1/ mice clearly demonstrated that
other adaptive mechanisms in addition to antibody production
could play a major protective role during VEEV infection.
Recovery in MT mice is associated with dramatic reduc-
tion of viral titers in the brain and clearance of infectious virus
in the spinal cord. Persistent CNS infection by wild-type
VEEV in mice has not been previously reported. The unex-
pected recovery observed in V3533-infected MT mice led us
to ask whether the observed recovery was associated with
clearance of virus from the CNS or the establishment of viral
persistence. To answer this question, we infected MT mice
subcutaneously in the footpad with 103 PFU of V3533 and then
sacrificed animals at various times postinfection and assessed
viral burden in relevant tissues by plaque assay.
The pattern of early V3533 replication and dissemination
observed in MT mice differed somewhat from the classic
biphasic course of infection that has previously been seen in
VEEV-infected immunocompetent mice (1). Virus was first
seen in the draining popliteal lymph node within 12 h of inoc-
ulation and in the spleen and serum by 24 h. Rather than being
rapidly cleared from these compartments, as is the case with
C57BL/6 mice, infectious V3533 remained detectable in both
serum and spleen for weeks following inoculation (Fig. 3A). Of
6 mice examined at 15 weeks postinfection, virus was still
detectable in serum (4/6) and spleen (2/6) by plaque assay
(Fig. 3B).
V3533 first appeared in the brains of MT mice around 24 h
postinfection and rapidly reached peak titers of around 106
PFU/g by day 4. The appearance of virus in the spinal cord was
slightly delayed, with infectious virus first detectable at 48 h
postinfection and peak titers being reached at day 6 (Fig. 3A).
Thus, the kinetics of neuroinvasion and initial replication of
the virus within the CNS were similar to those observed in
C57BL/6 mice. Between days 6 and 8, however, titers in both
brain and spinal cord began to fall and by day 15 postinfection
had been reduced to within 1 log of the limit of detection.
Following this initial reduction of viral titers within the CNS,
infectious virus was cleared from the spinal cord between days
15 and 30 postinfection but continued to persist in the brains of
the majority of animals tested through week 15 (day 105),
indicating the development of a chronic infection (Fig. 3B).
This divergence in the abilities of the brain and spinal cord to
clear virus in the absence of antibody mirrors what has been
reported previously in a study of Sindbis virus infection in
these mice (5).
Given that MT mice were able to control V3533 infection
within the CNS and recover from infection, we next asked
whether the mortality observed in V3533-infected Rag1/
mice was due to an inability to control viral replication. To
answer this question, we directly compared both systemic and
CNS titers between MT and Rag1/ mice at days 6 and 25
following subcutaneous infection with 103 PFU of V3533.
While viral titers were high at day 6 postinfection in both MT
and Rag1/ mice, by day 25 MT mice were able to reduce
titers in both serum and the brain substantially, while Rag1/
mice continued to maintain extremely high titers in both tis-
sues, potentially explaining the enhanced mortality rate in
these mice (Fig. 3C).
Reduction in viral CNS titers occurs concurrently with an
influx of inflammatory monocytes and T cells. The dramatic
reductions in CNS titers in the absence of antivirus antibody
led us to ask which immune cell populations were responsible.
We first identified leukocyte populations present in the brains
and spinal cords of V3533-infected mice over the course of
infection. MT mice were infected subcutaneously in the foot-
pad with 103 PFU of V3533. At different times postinfection,
infected animals were sacrificed and CNS-infiltrating leuko-
cytes were isolated. Different leukocyte populations were then
identified by surface phenotype and quantified by flow cytom-
etry (Fig. 4A).
The vast majority of leukocytes in the uninfected CNS were
identified as resting microglia, defined as CD11b CD45lo
MHC class IIlo, with minimal numbers of other populations
being detectable (17, 49). Following invasion of the CNS by
V3533, however, this picture changed dramatically. Between
days 4 and 10 postinfection, a massive expansion in a CD11b
CD45hi Ly-6G MHC class IIhi population, defined as inflam-
matory monocytes, was observed (16, 29, 49). This population
increased in both number and activation state, as assessed by
MHC class II expression, over this time period (Fig. 4B and
data not shown) (55). Between days 6 and 10 postinfection, the
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numbers of CD4 and CD8 T cells within the CNS increased
from barely detectable to 106 cells/brain and 105 cells/spinal
cord. After peaking at day 10, these inflammatory cell popu-
lations began rapidly contracting, with inflammatory mono-
cytes and T cell populations exhibiting a 5-to-10-fold decrease
in numbers by day 15 postinfection (Fig. 4B). Interestingly, the
period during which infected MT mice exhibited increasingly
severe disease signs and weight loss corresponded in time pre-
cisely to the period during which inflammatory monocytes and
T cell numbers within the CNS expanded, while the onset of
recovery in those animals corresponded to the contraction of
those cell populations (Fig. 2).
Due to the persistence of low levels of infectious virus in the
brains of recovered MT mice, we asked whether different
inflammatory cell populations were retained in the CNS during
the chronic phase of the infection. Comparing total cell num-
bers in the brains of MT mice 70 days after infection with
V3533 with those from mock-infected MT mice, we found
significantly elevated numbers of inflammatory monocytes and
CD4 and CD8 T cells, but not microglia, in the infected
group. In the spinal cord samples, all cell populations tested
were significantly elevated above mock-infection levels (Fig.
4C; P 	 0.05 [Mann-]Whitney). Additionally, microglia and
inflammatory monocytes from the persistently infected mice
showed significantly higher levels of MHC class II staining
relative to mock-infection levels, indicating that they retained
an activated phenotype (P 
 0.0286 [Mann Whitney]; data not
shown).
T cells are required for control of V3533 infection and re-
covery in MT mice. Numerous findings from studies demon-
FIG. 3. Recovery in MT mice is associated with control of viral replication in the brain and clearance in the spinal cord. Female MT or
Rag1/ mice (7 to 10 weeks old) were inoculated with 103 PFU of V3533 by injection in the left rear footpad. (A) At the time points indicated,
serum, spleen, brain, and spinal cord samples were collected from infected MT mice and homogenized. The amount of infectious virus present
in the serum, spleen, brain, and spinal cord samples was then quantified by plaque assays of BHK-21 cells. Data points represent individual tissue
titers pooled from two independent experiments. (B) Tissue titers from infected MT mice at day 105 postinfection. (C) Comparison of tissue titers
between MT and Rag1/ mice. Data are presented as the means  SEM of titer values from 3 to 4 animals per group. In all cases, dotted lines
represent the limit of detection.
4560 BROOKE ET AL. J. VIROL.
strating the importance of T cells in mediating antiviral immu-
nity in other viral systems, as well as the dramatic difference in
survival rates between MT and Rag1/ mice that we ob-
served, suggested that T cells are required for the recovery
observed in V3533-infected MT mice. It was also possible
that the relative contributions of CD4 and CD8 populations
to control of the infection and recovery differed. To address
these questions, we treated MT mice with depleting antibod-
ies against CD3, CD4, or CD8 or with an isotype control
antibody. Weight loss and disease score were observed for 25
days following infection, at which point surviving mice were
sacrificed and assayed for viral burden in the CNS as well as in
serum. The efficacy of the depletion treatments was also as-
sessed at the termination of the experiment by flow cytometric
analysis of splenocytes (Fig. 5A).
In terms of disease outcome, the antibody isotype control
group was indistinguishable from the untreated MT mouse
group following V3533 infection, with animals developing the
same overt signs of severe encephalomyelitis and then recov-
ering (Fig. 2 and 5B). The CD3-depleted group immediately
began exhibiting signs of illness upon infection, including
weight loss, hunching, ruffling, and ataxia. These disease signs
closely mirrored what was observed in V3533-infected
Rag1/ mice, without the convulsions, conjunctivitis, and
hind limb paresis observed in infected MT mice. Also, in
similarity to the disease observed in Rag1/ animals, illness in
FIG. 4. Reduction of viral titers in the CNS coincides with an influx of T cells and inflammatory monocytes. Female MT mice (7 to 10 weeks
old) were inoculated with 103 PFU of V3533 or diluent alone by injection in the left rear footpad. At various time points postinfection, mice were
perfused with PBS and CNS-infiltrating leukocytes were isolated. Infiltrating cells were stained for various surface markers and analyzed by flow
cytometry. (A) Representative dot plots illustrating the gating scheme used to define cell populations. (B) Total numbers of microglia (CD11b/
CD45lo), inflammatory monocytes (CD11b/CD45hi), CD4 T cells (CD3/CD4), and CD8 T cells (CD3/CD8) isolated from brain and
spinal cord samples. For each time point, data are presented as the means  the standard errors of the results obtained with 3 to 4 mice and are
representative of 2 independent experiments. (C) Comparison of total cell numbers of indicated infiltrating leukocyte populations between
mock-infected mice (left bar) and V3533-infected mice (right bar) 70 days postinfection. Data are presented as means  standard errors of the
results obtained with four animals per group. *, P 	 0.05 by Mann-Whitney testing.
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the CD3-depleted group was prolonged but generally suble-
thal, with 3 of 4 animals still alive at the termination of the
experiment at day 25 postinfection. Those surviving animals
appeared to be nearing death, however, suggesting that lethal-
ity would have been 100% had the experiment been allowed to
continue. The one significant difference observed between the
CD3-depleted group and Rag1/ mice was that the onset of
disease was much more rapid in the CD3-depleted group, with
signs of fever and weight loss easily observable by 24 h postin-
fection (Fig. 2 and 5B and data not shown). This was most
likely not an artifact of the depletion, as both the CD4- and
CD8-depleted groups exhibited the same delay between infec-
tion and disease onset as untreated MT mice.
In order to more directly examine the role of T cells in
controlling V3533 infection in MT mice, we compared viral
burdens at 25 days postinfection both within the CNS and
systemically between the different depleted groups with those
in the control group (Fig. 5C). As expected, based on infection
of untreated MT mice, the antibody isotype control-treated
group showed low to undetectable viral burdens in the brain
FIG. 5. T cells are required for control of infection and recovery in MT mice. Female MT mice (7 to 10 weeks old) were treated with
depleting antibodies against CD3, CD4, or CD8 or with an isotype control antibody and then inoculated with 103 PFU of V3533 by injection in
the left rear footpad. Depletion treatments were continued for 25 days postinfection, at which point the experiment was terminated. (A) Rep-
resentative dot plots of CD3 splenocytes from each group, taken at day 25 postinfection. (B) Effect of T cell depletions on weight loss following
V3533 infection. Data represent means  standard errors of the results obtained with 4 to 5 animals per group. (C) Infectious virus from tissues
harvested 25 days postinfection, assessed by plaque assays on BHK-21 cells. Each data point represents a single animal, with bars indicating the
geometric means. *, P 	 0.05 compared to control by Mann Whitney testing.
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and serum and no detectable infectious virus in the spinal cord.
The CD3-depleted mice, however, demonstrated a complete
inability to control the infection, with titers in all three com-
partments tested ranging from 105 PFU/ml in the serum to 107
PFU/g in the brain. These results clearly demonstrated a re-
quirement for the T cell compartment in controlling V3533
infection in the absence of antibody.
Both CD4 and CD8 T cells are required for effective
control of V3533 infection in MT mice. Initial disease severity
in both CD4- and CD8-depleted groups appeared to be some-
what intermediate between the levels of severity seen with the
control and CD3-depleted groups. During the time of peak
disease severity (days 9 to 10), both the CD4- and CD8-de-
pleted groups lost significantly less weight than the antibody
isotype control-treated group (P 	 0.05 [Mann-Whitney]), and
neither group developed the conjunctivitis and/or hind limb
paresis that were characteristic of V3533 infection in untreated
MT mice (Fig. 5B and data not shown). This indicated that
both CD4 and CD8 T cells together were required for the
most extreme pathology observed in MT mice following
V3533 infection.
While the CD4 and CD8 depletion treatments reduced the
severity of V3533-induced disease during the early stages of
infection, they also appeared to reduce the ability of those
animals to recover compared with the control group (Fig. 5B).
At the termination of the experiment, 25 days postinfection,
one of five CD4-depleted mice had already succumbed to in-
fection, and the survivors were steadily losing weight, indicat-
ing that they were not successfully controlling the infection.
The CD8-depleted group, while appearing to have recovered
more fully than the CD4-depleted group at first, also had
begun to deteriorate again by the end of the experiment, re-
sulting in significantly lower weights and significantly higher
disease scores compared with the antibody isotype control
group at day 25 (both P 	 0.05 [Mann-Whitney]). Although
the experiment was not extended long enough to determine
final survival rates for the different groups, the status of the
CD4- and CD8-depleted groups at the termination of the ex-
periment strongly suggested that both CD4 and CD8 T cell
populations were required for complete recovery from V3533
infection.
Having established the necessity of T cells for effective con-
trol of V3533 and recovery, the relative contributions of the
CD4 and CD8 compartments to the control of the virus
both systemically and within the CNS were determined (Fig.
5C). In the serum at day 25 postinfection, mean virus titers in
both the CD4- and CD8-depleted groups were roughly 3 logs
lower than in the CD3-depleted group, though still elevated
above those in the antibody isotype control group, indicating
that each population was able to exert substantial control over
systemic replication of V3533 and that both populations were
required for maximal control. In brain tissue, mean virus titers
in mice depleted of CD8 cells were statistically indistinguish-
able from those of the antibody isotype control group (P 

0.1761 [Mann-Whitney]). Brain titers in the CD8-depleted
group were significantly lower than in the CD3-depleted group,
however (P 
 0.0357 [Mann-Whitney]). In the CD4-depleted
group, titers were significantly elevated above those seen with
both the control and the CD8-depleted groups (P 
 0.0294 and
0.0159, respectively [Mann-Whitney]) but were indistinguish-
able from those seen with the CD3-depleted group (P 
 0.0571
[Mann-Whitney]). In spinal cord tissue, we observed a similar
trend in which titers in CD8-depleted mice were significantly
lower than those of the CD3-depleted group but titers in CD4-
depleted mice were not statistically distinguishable from those
in the CD3-depleted group (P 
 0.4 and P 
 0.0357, respec-
tively [Mann-Whitney]) (Fig. 5C). Together, these results sug-
gest that within the CNS, the CD4 compartment contributes
the majority of the T cell-associated antiviral activity and that
both CD4 and CD8 cells are required for maximal control.
CD4 T cells are the primary source of T cell-associated
IFN- within the brain. The apparent differences in antiviral
activity observed between CD4 and CD8 cells within the
CNS might be explained by differences in expression of cyto-
kines or other indicators of effector function. To address this
possibility, we isolated T cells from the brains of V3533-in-
fected MT mice at days 8, 15, and 70 postinfection and
assessed expression of IFN-, TNF-, IL-2, IL-10, and IL-17 by
intracellular cytokine staining. We also looked at surface ex-
pression of CD69 and CD107a as markers of recent activation
and degranulation, respectively. Day 8 was chosen to provide a
snapshot of T cell behavior during the peak of antiviral activity,
as T cell numbers in the CNS were increasing and viral titers
were decreasing at this time. Day 15 represented a point after
which both viral titers and T cell numbers within the CNS had
decreased substantially and recovery had begun. Day 70 was
chosen to represent a point well into the chronic phase of
infection.
T cell behavior within the brains of V3533-infected mice was
determined using two complementary approaches. The first
was to nonspecifically stimulate brain-infiltrating T cells with
PMA and ionomycin for 6 h ex vivo prior to flow cytometric
analysis to determine how these cells were capable of respond-
ing (Fig. 6A). Using this approach, it appeared that CD4 and
CD8 cells were programmed to respond similarly to V3533
infection within the brain. Large numbers of IFN-- and TNF-
-producing CD4 and CD8 cells were detected whereas
IL-17- and IL-10-producing cells were much less prevalent,
indicating that both the CD4 and CD8 cell populations
appeared to be participating in a predominantly Th1-skewed
response. IL-2 production was minimal, in accordance with
previous findings for Sindbis infection (26). The numbers of
IFN-- and TNF--producing CD4 and CD8 cells were
roughly equivalent at day 8, but by day 15 the number of CD8
cells producing both cytokines was approximately 2-fold higher
than the number of CD4 cells producing both cytokines,
reflecting an overall increase in the ratio of total CD8 cells to
CD4 cells at this time point. At all time points, a higher
percentage of CD8 cells than CD4 cells stained positive for
surface expression of the recent degranulation marker
CD107a. These results suggest that brain-infiltrating CD4
and CD8 T cells were similar in their abilities to produce
IFN- and TNF- ex vivo during the acute phase response to
V3533 and that the degranulation activity of CD8 T cells was
superior to that of CD4 cells. Both CD4 and CD8 T cells
retained multiple effector capabilities well into the chronic
phase of VEEV infection, indicating that the phenomenon of
T cell exhaustion was not occurring in this system (Table 1).
The caveat with results obtained by PMA-ionomycin treat-
ment, however, is that they represent only how T cells are
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programmed to respond but not how they actually behave in
vivo.
A second approach gave a more direct measurement of how
T cells were actually behaving in vivo. Rather than being
treated with PMA and ionomycin following isolation, brain-
infiltrating T cells were treated only with brefeldin A, with or
without monensin, prior to flow cytometric analysis (Fig. 6B).
No external stimulus was provided. While this treatment prob-
ably resulted in artificially low levels of detectable expres-
sion due to the time lag between sacrifice of the animal and
cell fixation, we feel that any results observed using this
method were the direct result of the stimuli and regulatory
signals present within the brains of V3533-infected mice.
Brain-infiltrating T cells analyzed in the absence of ex vivo
stimulus exhibited a dramatically different pattern of IFN-
and CD107a expression compared to that observed follow-
ing PMA-ionomycin treatment. At days 8, 15, and 70 postin-
fection, significant IFN- expression was detectable only
within the CD4 population. IFN--positive CD8 T cells
were undetectable at all time points. In addition, a larger
percentage of CD4 cells expressing surface CD107a than
of CD8 cells was detected during the acute phase. Finally,
IL-2-, IL-17-, and IL-10-expressing cells were sparse in both
FIG. 6. CD4 T cells are the main producers of T-cell-associated IFN- within the brains of V3533-infected MT mice. Female MT mice (7
to 10 weeks old) were inoculated with 103 PFU of V3533 by injection in the left rear footpad. At the times indicated, mice were perfused with PBS
and brain-infiltrating leukocytes were isolated. (A and B) Harvested cells were then pooled and either cultured in the presence of PMA-ionomycin
for 6 h with brefeldin A with or without monensin added for the final 4 h (A) or cultured in the presence of brefeldin A with or without monensin
with no additional stimulus for 4 h (B). Following treatment, cells were surface stained for CD3, CD4, and CD8 and then stained for the
intracellular presence of multiple cytokines. Each bar represents the number of cells of a given cell type that stained as positive for the indicated
cytokine-surface marker per brain (days 8 and 15) or the percentage of pooled cells that stained as positive (day 70). (C) Percentages of T cells
positive for CD69 surface expression in the absence of ex vivo stimulation. Data shown were generated in a single experiment but are representative
of 2 to 3 independent experiments.
TABLE 1. Percentages of brain-infiltrating T cells expressing the
indicated cytokines at day 70 postinfection
Cytokine









IFN- 62.03 1.92 77.96 0.0
TNF- 40.51 1.92 62.84 3.28
IL-2 16.91 1.32 11.19 0.0
IL-17 0.0 0.0 0.0 0.75
IL-10 18.75 0.4 0.93 0.57
CD107a 4.81 0.2 26.01 0.0
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CD4 and CD8 T cells. Together, these results indicate
that during the acute phase of the response to V3533 infec-
tion within the brain, CD4 T cells produced more IFN-
and had higher levels of degranulation activity than CD8 T
cells, potentially explaining why these cells exhibited anti-
VEEV activity of greater potency.
While the lack of known T cell epitopes prevented us from
directly examining VEEV-specific T cells, we felt that the use
of CD69 staining provided a reasonable alternative. CD69
expression on T cells serves as a marker of recent encounter
with cognate antigen and should not be expressed on bystander
T cells (47). At each time point examined, CD69 cells con-
stituted roughly 50 to 80% of all CD4 and CD8 T cells
within the brain (Fig. 6C). This is consistent with the majority
of brain-infiltrating T cells being VEEV-specific during both
the acute and chronic phases of infection.
DISCUSSION
While the important protective role of B cells and virus-
specific antibodies during neuronotropic alphavirus infection
has been well established, the role of T cells remains relatively
ill defined. Work with avirulent Sindbis virus has suggested
that T cells might directly act to limit viral infection within the
CNS by noncytolytic mechanisms; however, the results of stud-
ies using virulent strains of Sindbis or VEEV were contradic-
tory, suggesting instead that T cells might either act to enhance
pathology or play no significant role whatsoever (5, 28, 44).
Previous studies evaluating the immune response to VEEV
infection have been hampered by the lack of a model system in
which successful control of infection could be reliably ob-
served. To better understand the role of T cells during a suc-
cessful immune response to acute VEEV infection, we utilized
V3533, a mutant of VEEV that is capable of invading the CNS
from the periphery and yet only induces mild, transient disease
in immunocompetent mice. We feel that this provides a more
relevant model of the results of VEEV-induced disease in
humans than the universal lethality observed in mice infected
with wild-type VEEV strains, as natural infections of humans
very rarely progress to overt encephalomyelitis and death (58).
Using V3533 infection of mice as a model of successful recov-
ery from VEEV-induced encephalomyelitis, we asked whether
T cells played a significant role during recovery from VEEV
infection, independent from any effect on antibody production.
We observed that B cell-deficient MT mice were able to
recover from V3533 infection while T cell-depleted MT mice
were not, clearly demonstrating that T cells could facilitate
clinical recovery from VEEV-induced encephalomyelitis in the
absence of antibody.
We chose to carry out these studies using MT mice, rather
than B cell-depleted immunocompetent mice, in order to en-
sure that antibody production was completely absent. Given
the highly protective effects that antibodies demonstrated in
other alphavirus infection models, we were concerned that
even a small percentage of endogenous B cells that survived a
depletion treatment might exert enough of an effect to con-
found the potentially subtle T cell-associated effects in which
we were interested (32). The use of MT mice as “B cell-
deficient” mice is complicated by the observation that these
mice exhibit various T cell deficiencies relative to wild-type
mice (2). We cannot rule out the possibility that these defects,
which affect both expansion and function in CD4 and CD8
T cells, might contribute to the viral persistence that we ob-
served. However, the fact that T cells are able to control V3533
infection and facilitate recovery in MT mice despite these
strain-specific deficiencies strengthens our conclusion that T
cells contribute a significant antiviral effect during V3533 in-
fection.
Viral infection of CNS neurons presents a unique problem
for the immune system in that they are absolutely essential for
host function and yet are not easily replaced (34). As a result,
widespread immune-mediated cytolysis of infected cells can
present a greater threat to host viability than the virus itself
(10). In the case of infection with a highly virulent virus, the
benefits of cytolytic clearance mechanisms might be worth the
cost in enhanced pathology; however, it appears that the mam-
malian immune system has also evolved noncytolytic mecha-
nisms of T cell-mediated clearance. In particular, studies
with Sindbis virus, Theiler’s murine encephalomyelitis virus
(TMEV), and measles virus have all implicated T cell-associ-
ated IFN- production in mediating noncytolytic clearance of
virus from infected neurons (7, 38, 42). The studies described
here clearly demonstrated that, during V3533 infection, T cells
were able to significantly restrict viral replication within the
brain and clear infectious virus from the spinal cord, thus
facilitating recovery from a severe viral encephalomyelitis.
While this reduction in CNS titers was clearly associated with
disease signs of greater severity than were observed in Rag1/
mice, the rapid onset of recovery and the absence of long-lived
sequelae within the brain suggest that control of the infection
was not achieved simply by destruction of infected neurons.
The failure of MT mice to fully clear infectious virus from
the CNS mirrors what has been previously observed in MT
mice infected with Sindbis virus (5). The ability of these mice
to recover from V3533-induced encephalomyelitis despite the
continuing presence of infectious virus within the CNS as well
as in the rest of the system raises a number of questions. The
most obvious is this: what are the cellular reservoirs of virus
that prevent total clearance? Studies with Sindbis virus have
indicated that neuronal subpopulations within the CNS are
differentially susceptible to IFN--mediated clearance (8).
Whether these differences are due to intrinsic differences in
the IFN--signaling network within these cells or to some other
mechanism remains to be determined. If there is a stable
reservoir of clearance-refractory neurons that are responsible
for the observed persistence, how are those cells able to survive
prolonged infection with a cytolytic virus? Despite the pres-
ence of robust antiapoptotic programming within mature neu-
rons, virulent strains of VEEV are able to induce widespread
neuronal death (10, 22, 27). It may be that V3533 is less
efficient at overcoming these mechanisms, thus allowing long-
term survival of infected neurons. If this is the case, under-
standing the molecular basis of this difference will be of great
interest. Another issue that remains unresolved is the extent to
which host neurological function is compromised by the ongo-
ing persistent infection and accompanying low-level inflamma-
tory response (40). While MT mice appear to recover fully
from V3533-induced clinical disease, it is possible that a more
in-depth evaluation of cognitive function in the animals that
recover might reveal subtle defects.
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Given the continuing presence of infectious virus within the
CNS of recovered MT mice, it is not surprising that activated
T cells were retained within the brain and spinal cord. What
was somewhat surprising was that both CD4 and CD8 T
cells retained functionality, as determined by IFN- expres-
sion, as long as 70 days following infection. The loss of T cell
function, specifically IFN- expression, has been well docu-
mented in other models of persistent viral infection and is
thought to result from prolonged antigen exposure (6, 36, 51).
In this model of persistent VEEV infection, however, long-
term antigen exposure, as indicated by sustained CD69 expres-
sion, was not sufficient to induce exhaustion. A recent study
that examined T cell responses to chronic mouse hepatitis virus
infection of the CNS also observed long-term maintenance of
T cell function despite ongoing antigenic stimulation, suggest-
ing that some aspect of the CNS regulatory environment might
prevent the development of the exhaustion phenotype ob-
served in other systems (61).
Another notable aspect of the T cell response that we ob-
served during the subclinical chronic phase of the infection was
a shift in CD8/CD4 T cell ratios. While this ratio was
roughly 1:1 during the acute phase of the response within the
CNS, by day 20 postinfection it had risen to about 3:1 and by
day 70 had reached nearly 10:1. One possible explanation for
this finding could be increased susceptibility to apoptosis
among cells of the CD4 population. Studies performed in the
context of acute lymphocytic choriomeningitis (LCMV) infec-
tion showed that CD4 memory cells have lower levels of Bcl-2
expression than CD8 memory cells and that this corresponds
to a decline of greater rapidity in CD4 T cell numbers over
time (24). Another possible explanation is that MHC class I
and MHC class II expression within the CNS might be differ-
entially regulated during the development of viral persistence
(39). Since viral antigen presentation is likely to be required for
maintenance of T cell populations during chronic infection, it
may be that a reduction in MHC class II-restricted presenta-
tion could result in the gradually diminishing CD4 T cell
numbers that we observed (50). More work is needed to de-
scribe the dynamics of antigen presentation within the CNS
during chronic viral infection.
It has been firmly established that the CNS represents an
especially unique microenvironment in which extremely tight
regulation of host immune responses is essential for continued
host viability (9, 37). Numerous mechanisms, including re-
stricted expression of MHC class I and class II by neurons and
the constitutive production of transforming growth factor beta
(TGF-) and immune-suppressive gangliosides by glial cells,
act to limit both the magnitude and duration of inflammatory
responses, thereby protecting against excessive immune pa-
thology (15, 25, 30, 37, 48). The complex regulatory environ-
ment within the CNS might explain our observation that CD4
T cells appear to have been providing the majority of T cell-
associated antiviral activity in our system. Despite both T cell
populations having been clearly primed to produce IFN-, as
evidenced by the response to PMA-ionomycin treatment, the
absence of detectable IFN- expression by unstimulated brain-
infiltrating CD8 T cells during the acute response to V3533
suggests that CD4 and CD8 cells are subject to differential
regulation within the brain. This observation could be ex-
plained by a failure of infected neurons to upregulate MHC
class I, preventing antigen encounter, but this is unlikely, as the
vast majority of CD8 T cells retain a CD69 phenotype
during both the acute and chronic phases of the response to
V3533, indicating a recent encounter with cognate antigen. It
seems more likely that some environmental factor is specifi-
cally limiting IFN- production by CD8 cells within the brain.
There is precedent for this, as CNS-infiltrating CD4 T cells
responding to Sindbis virus infection appear deficient in IL-2
expression, compared with CD4 T cells in the periphery (26).
Other studies have shown that T cells primed by brain-resident
microglia take on a phenotype that is distinct from that seen
with T cells primed by other antigen-presenting cell popula-
tions (16). Clearly, further work is needed to better define the
regulatory elements within the CNS that dictate T cell function
during VEEV infection.
Our observation that, within this highly reductionist model,
CD4 cells played a significantly more potent antiviral role
than CD8 cells in response to V3533 correlated with substan-
tially higher levels of IFN- expression and signs of recent
degranulation. This differs from results obtained in studies
performed with Sindbis virus-infected mice, where CD4 and
CD8 T cells appeared to have had equivalent effects on viral
titers within the CNS (5). Based on our CD8 depletion studies
of MT mice, CD4 T cells appear to exert a considerable
antiviral effect, independent of any role in helping B cell or
CD8 T cell responses. This effect is most likely mediated
primarily by IFN- signaling within infected neurons, in simi-
larity to what has been described in Sindbis virus, Borna virus,
TMEV, and measles virus studies (7, 23, 38, 42). However, we
cannot rule out additional mechanisms. One possible alterna-
tive mechanism could involve the release of lytic granules as
CD4 T cells and, to a lesser extent, CD8 T cells both ex-
hibited signs of recent degranulation during and after the
acute-phase response. Lytic granule release could act to clear
V3533 from infected neurons either by cytotoxic mechanisms
(i.e., perforin release), as has been described to occur during
West Nile virus infection, or by nonlethal mechanisms, as has
been described to occur during HSV-1 infection (31, 52). A
second possible alternative mechanism is that CD4 T cells,
possibly through IFN- expression, might act to enhance
monocyte-microglia responses to the virus, as has been ob-
served following LCMV infection of the CNS (33). Obviously,
these different mechanisms are not mutually exclusive. Given
that neurons do not express MHC class II, the mechanism by
which CD4 T cells recognize V3533-infected neurons also
remains unclear (41).
In summary, our results confirm the importance of antiviral
antibodies in limiting disease following neuronotropic alpha-
virus infection but also clearly demonstrate that T cells can
facilitate recovery from severe viral encephalomyelitis in the
absence of antibodies. The recovery that we observed in
V3533-infected MT mice was associated with a dramatic re-
duction in viral titers within the CNS, followed by the estab-
lishment of a persistent subclinical infection. These results
demonstrate for the first time that T cells are able to directly
control infection by a neuronotropic virus that causes enceph-
alomyelitis in humans. We also showed that, in the context of
VEEV infection, the majority of T cell-associated antiviral
activity resides within the CD4 population, possibly due to
significantly enhanced IFN- expression in these cells com-
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pared with CD8 cells. Taken together, these findings suggest
that the promotion of T cell effector function, within both
CD4 and CD8 populations, should be an important consid-
eration when designing and evaluating new vaccines against
encephalitic alphaviruses.
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